vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and WESTPORT FUEL SYSTEMS INC. (WPRT). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $12.5M, roughly 1.6× WESTPORT FUEL SYSTEMS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — -177.4% vs -274.8%, a 97.4% gap on every dollar of revenue. On growth, WESTPORT FUEL SYSTEMS INC. posted the faster year-over-year revenue change (-11.4% vs -11.5%). WESTPORT FUEL SYSTEMS INC. produced more free cash flow last quarter ($-6.4M vs $-23.1M).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Westport Innovations is a company that develops alternative fuel, low-emissions technologies to allow engines to operate on clean-burning fuels such as compressed natural gas (CNG), liquefied natural gas (LNG), hydrogen and biofuels such as landfill gas. Headquartered in Vancouver, British Columbia, Canada, where the company was founded, Westport also has facilities in France, Sweden, Italy, China, Australia and the United States.

LAB vs WPRT — Head-to-Head

Bigger by revenue
LAB
LAB
1.6× larger
LAB
$19.6M
$12.5M
WPRT
Growing faster (revenue YoY)
WPRT
WPRT
+0.1% gap
WPRT
-11.4%
-11.5%
LAB
Higher net margin
LAB
LAB
97.4% more per $
LAB
-177.4%
-274.8%
WPRT
More free cash flow
WPRT
WPRT
$16.6M more FCF
WPRT
$-6.4M
$-23.1M
LAB

Income Statement — Q3 FY2025 vs Q2 FY2025

Metric
LAB
LAB
WPRT
WPRT
Revenue
$19.6M
$12.5M
Net Profit
$-34.7M
$-34.3M
Gross Margin
48.5%
6.7%
Operating Margin
-168.5%
-8.1%
Net Margin
-177.4%
-274.8%
Revenue YoY
-11.5%
-11.4%
Net Profit YoY
-28.8%
-690.4%
EPS (diluted)
$-0.09
$-1.98

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
WPRT
WPRT
Q3 25
$19.6M
Q2 25
$21.8M
$12.5M
Q1 25
$40.8M
Q3 24
$22.1M
$4.9M
Q2 24
$22.5M
$14.1M
Q1 24
$45.5M
Q4 23
$28.2M
Q3 23
$25.4M
Net Profit
LAB
LAB
WPRT
WPRT
Q3 25
$-34.7M
Q2 25
$-33.5M
$-34.3M
Q1 25
$-26.0M
Q3 24
$-26.9M
$-3.9M
Q2 24
$-45.7M
$5.8M
Q1 24
$-32.2M
Q4 23
$-19.8M
Q3 23
$-21.0M
Gross Margin
LAB
LAB
WPRT
WPRT
Q3 25
48.5%
Q2 25
48.8%
6.7%
Q1 25
48.4%
Q3 24
54.9%
13.6%
Q2 24
46.1%
16.7%
Q1 24
53.1%
Q4 23
47.6%
Q3 23
44.0%
Operating Margin
LAB
LAB
WPRT
WPRT
Q3 25
-168.5%
Q2 25
-118.1%
-8.1%
Q1 25
-80.8%
Q3 24
-120.9%
-43.9%
Q2 24
-134.5%
-54.9%
Q1 24
-132.2%
Q4 23
-75.9%
Q3 23
-83.5%
Net Margin
LAB
LAB
WPRT
WPRT
Q3 25
-177.4%
Q2 25
-153.7%
-274.8%
Q1 25
-63.8%
Q3 24
-122.0%
-79.3%
Q2 24
-203.3%
41.2%
Q1 24
-70.6%
Q4 23
-70.2%
Q3 23
-82.8%
EPS (diluted)
LAB
LAB
WPRT
WPRT
Q3 25
$-0.09
Q2 25
$-0.09
$-1.98
Q1 25
$-0.07
Q3 24
$-0.07
$-0.22
Q2 24
$-0.12
$0.34
Q1 24
$-0.27
Q4 23
$-0.24
Q3 23
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
WPRT
WPRT
Cash + ST InvestmentsLiquidity on hand
$129.4M
$6.1M
Total DebtLower is stronger
$977.0K
Stockholders' EquityBook value
$399.7M
$108.9M
Total Assets
$539.6M
$272.1M
Debt / EquityLower = less leverage
0.01×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
WPRT
WPRT
Q3 25
$129.4M
Q2 25
$158.6M
$6.1M
Q1 25
$150.9M
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Q4 23
$51.7M
Q3 23
$79.7M
Total Debt
LAB
LAB
WPRT
WPRT
Q3 25
Q2 25
$977.0K
Q1 25
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Q4 23
$63.5M
Q3 23
$64.6M
Stockholders' Equity
LAB
LAB
WPRT
WPRT
Q3 25
$399.7M
Q2 25
$424.5M
$108.9M
Q1 25
$454.6M
Q3 24
$489.3M
$149.3M
Q2 24
$510.3M
$151.5M
Q1 24
$577.3M
Q4 23
$-148.1M
Q3 23
$-131.7M
Total Assets
LAB
LAB
WPRT
WPRT
Q3 25
$539.6M
Q2 25
$557.0M
$272.1M
Q1 25
$579.6M
Q3 24
$681.5M
Q2 24
$708.7M
Q1 24
$777.7M
Q4 23
$323.1M
Q3 23
$339.3M
Debt / Equity
LAB
LAB
WPRT
WPRT
Q3 25
Q2 25
0.01×
Q1 25
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×
Q4 23
Q3 23

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
WPRT
WPRT
Operating Cash FlowLast quarter
$-22.2M
$-5.6M
Free Cash FlowOCF − Capex
$-23.1M
$-6.4M
FCF MarginFCF / Revenue
-118.1%
-51.6%
Capex IntensityCapex / Revenue
4.5%
6.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
WPRT
WPRT
Q3 25
$-22.2M
Q2 25
$-20.7M
$-5.6M
Q1 25
$-30.3M
Q3 24
$-27.9M
$-11.7M
Q2 24
$-39.0M
$1.5M
Q1 24
$-62.5M
Q4 23
$-14.1M
Q3 23
$-11.4M
Free Cash Flow
LAB
LAB
WPRT
WPRT
Q3 25
$-23.1M
Q2 25
$-22.6M
$-6.4M
Q1 25
$-35.3M
Q3 24
$-30.1M
$-11.9M
Q2 24
$-41.0M
$262.0K
Q1 24
$-63.3M
Q4 23
$-14.1M
Q3 23
$-12.3M
FCF Margin
LAB
LAB
WPRT
WPRT
Q3 25
-118.1%
Q2 25
-103.6%
-51.6%
Q1 25
-86.6%
Q3 24
-136.4%
-243.4%
Q2 24
-182.2%
1.9%
Q1 24
-138.9%
Q4 23
-50.2%
Q3 23
-48.6%
Capex Intensity
LAB
LAB
WPRT
WPRT
Q3 25
4.5%
Q2 25
8.7%
6.6%
Q1 25
12.4%
Q3 24
10.2%
3.8%
Q2 24
8.6%
8.9%
Q1 24
1.7%
Q4 23
0.3%
Q3 23
3.6%
Cash Conversion
LAB
LAB
WPRT
WPRT
Q3 25
Q2 25
Q1 25
Q3 24
Q2 24
0.26×
Q1 24
Q4 23
Q3 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

WPRT
WPRT

Segment breakdown not available.

Related Comparisons